Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases

https://doi.org/10.1007/s10156-005-0408-9Get rights and content

Abstract

Bacteriophage (phage) therapy involves using phages or their products as bioagents for the treatment or prophylaxis of bacterial infectious diseases. Much evidence in support of the effectiveness of phage therapy against bacterial infectious diseases has accumulated since 1980 from animal model studies conducted in Western countries. Reports indicate that appropriate administration of living phages can be used to treat lethal infectious diseases caused by gram-negative bacteria, such as Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Vibrio vulnificus, and Salmonella spp., and gram-positive bacteria, such as Enterococcus faecium and Staphylococcus aureus. The phage display system and genetically modified nonreplicating phages are also effective for treatment of Helicobacter pylori and P. aeruginosa, respectively. In addition to phage particles per se, purified phage-encoded peptidoglycan hydrolase (lysin) is also reported to be effective for the treatment of bacterial infectious diseases caused by gram-positive bacteria such as Streptococcus pyogenes, S. pneumoniae, Bacillus anthracis, and group B streptococci. All phage lysins that have been studied to date exhibit immediate and strong bacteriolytic activity when applied exogenously. Furthermore, phage-coded inhibitors of peptidoglycan synthesis (protein antibiotics), search methods for novel antibacterial agents using phage genome informatics, and vaccines utilizing phages or their products are being developed. Phage therapy will compensate for unavoidable complications of chemotherapy such as the appearance of multidrug resistance or substituted microbism.

References (109)

  • J. Cao et al.

    Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth

    Biochem Biophys Acta

    (2000)
  • J. Kaneko et al.

    Complete nucleotide sequence and molecular characterization of the temperate staphylococcal bacteriophage ФPVL carrying Panton–Valentine leukocidin genes

    Gene (Amst)

    (1998)
  • H-W. Ackermann

    Tailed bacteriophages: the order Caudovirales

    Adv Virus Res

    (1998)
  • J.S. Soothill

    Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa

    Burns

    (1994)
  • S.I. Ahmad

    Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics

    Med Hypotheses

    (2002)
  • K. Hiramatsu et al.

    The emergence and evolution of methicillin-resistant Staphylococcus aureus

    Trends Microbiol

    (2001)
  • K. Hiramatsu et al.

    Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

    Lancet

    (1997)
  • J.E. Ross et al.

    Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program

    Diagn Microbiol Infect Dis

    (2005)
  • T. Nakai et al.

    Bacteriophage therapy of infectious diseases in aquaculture

    Res Microbiol

    (2002)
  • B. Leverentz et al.

    Optimizing concentration and timing of a phage spray application to reduce Listeria monocytogenes on honeydew melon tissue

    J Food Prot

    (2004)
  • B. Leverentz et al.

    Examination of bacteriophage as a biocontrol method for salmonella on fresh-cut fruit: a model study

    J Food Prot

    (2001)
  • R.J. Payne et al.

    Understanding bacteriophage therapy as a density-dependent kinetic process

    J Theor Biol

    (2001)
  • R.J. Weld et al.

    Models of phage growth and their applicability to phage therapy

    J Theor Biol

    (2004)
  • W.W. Navarre et al.

    Multiple enzymatic activities of the murein hydrolase from staphylococcal phage S6154211

    J Biol Chem

    (1999)
  • W.C. Summers

    Félix d’Herelle and the origins of molecular biology

    (1999)
  • K. Ho

    Bacteriophage therapy for bacterial infections. Rekindling a memory from the pre-antibiotics era

    Perspect Biol Med

    (2001)
  • A. Sulakvelidze et al.

    Bacteriophage therapy

    Antimicrob Agents Chemother

    (2001)
  • S. Slopek et al.

    Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986

    Arch Immunol Ther Exp

    (1987)
  • B. Weber-Dabrowska et al.

    Bacteriophage therapy of bacterial infections: an update of our institute's experience

    Arch Immunol Ther Exp

    (2000)
  • N. Chanishvili et al.

    Phages and experience for their application in the former Soviet Union

    (2002)

  • Phage therapy [editorial]

    Lancet

    (1983)
  • J. Lederberg

    Smaller fleas ad infinitum: therapeutic bacteriophage redux

    Proc Natl Acad Sci USA

    (1996)
  • R.M. Carlton

    Phage therapy: past history and future prospects

    Arch Immunol Ther Exp

    (1999)
  • R. Stone

    Bacteriophage therapy. Stalin's forgotten cure

    Science

    (2002)
  • C.R. Merril et al.

    The prospect for bacteriophage therapy in Western medicine

    Nat Rev Drug Discov

    (2003)
  • P.D. Thacker

    Set a microbe to kill a microbe: drug resistance renews interest in phage therapy

    JAMA

    (2003)
  • B.R. Levin et al.

    Population and evolutionary dynamics of phage therapy

    Nat Rev Microbiol

    (2004)

  • Renaissance phage [editorial]

    Nat Rev Microbiol

    (2004)
  • H-W. Ackermann et al.

    Viruses of prokaryotes. I. General properties of bacteriophages

    (1987)
  • H-W. Ackermann

    Frequency of morphological phage descriptions in the year 2000

    Arch Virol

    (2001)
  • S. Matsuzaki et al.

    A broad-host-range vibriophage, KVP40, isolated from sea water

    Microbiol Immunol

    (1992)
  • T. Inoue et al.

    A 26-kDa outer membrane protein, OmpK, common to Vibrio species is the receptor for a broad-host-range vibriophage, KVP40

    FEMS Microbiol Lett

    (1995)
  • S. Matsuzaki et al.

    Major capsid proteins of certain Vibrio and Aeromonas phages are homologous to the equivalent protein, gp23*, of coliphage T4

    Arch Virol

    (1999)
  • S. Matsuzaki et al.

    Vibriophage KVP40 and coliphage T4 genomes share a homologous 7-kbp region immediately upstream of the gene encoding the major capsid protein

    Arch Virol

    (1999)
  • M.S. Mitchel et al.

    Sequence analysis of bacteriophage T4 DNA packaging/terminase genes 16 and 17 reveals a common ATPase center in the large subunit of viral terminases

    Nucleic Acids Res

    (2002)
  • S. Matsuzaki et al.

    Characterization of a novel Vibrio parahaemolyticus phage, KVP241, and its relatives frequently isolated from seawater

    Microbiol Immunol

    (2000)
  • S. Matsuzaki et al.

    Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage S61542MR11

    J Infect Dis

    (2003)
  • J. Maniloff et al.

    Taxonomy of bacterial viruses: establishment of tailed virus genera and the order Caudovirales

    Arch Virol

    (1998)
  • T.G. Bernhardt et al.

    Genetic evidence that the bacteriophage S61542X174 lysis protein inhibits cell wall synthesis

    Proc Natl Acad Sci USA

    (2000)
  • T.G. Bernhardt et al.

    The lysis protein E of S61542X174 is a specific inhibitor of the MraY-catalyzed step in peptidoglycan synthesis

    J Biol Chem

    (2000)

    • Cited by (309)

    • Type I photodynamic antimicrobial therapy: Principles, progress, and future perspectives

      2024, Acta Biomaterialia

    • Surface engineering of mesoporous bioactive glass nanoparticles with bacteriophages for enhanced antibacterial activity

      2024, Colloids and Surfaces B: Biointerfaces

    • Nanomaterials-based photothermal therapies for antibacterial applications

      2023, Materials and Design

    • Characterization and genomic analysis of novel bacteriophage NK20 to revert colistin resistance and combat pandrug-resistant Klebsiella pneumoniae in a rat respiratory infection model

      2023, Life Sciences

    • Use of phages as antimicrobial agents

      2023, Molecular Medical Microbiology, Third Edition

    • Characterisation of broad-spectrum phiKZ like jumbo phage and its utilisation in controlling multidrug-resistant Pseudomonas aeruginosa isolates

      2022, Microbial Pathogenesis
    View all citing articles on Scopus
    View full text
    Copyright © 2005 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.